1. Home
  2. CPSS vs CRDF Comparison

CPSS vs CRDF Comparison

Compare CPSS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPSS
  • CRDF
  • Stock Information
  • Founded
  • CPSS 1991
  • CRDF 1999
  • Country
  • CPSS United States
  • CRDF United States
  • Employees
  • CPSS N/A
  • CRDF N/A
  • Industry
  • CPSS Finance: Consumer Services
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CPSS Finance
  • CRDF Health Care
  • Exchange
  • CPSS Nasdaq
  • CRDF Nasdaq
  • Market Cap
  • CPSS 164.5M
  • CRDF 144.4M
  • IPO Year
  • CPSS 1992
  • CRDF N/A
  • Fundamental
  • Price
  • CPSS $8.53
  • CRDF $2.05
  • Analyst Decision
  • CPSS
  • CRDF Strong Buy
  • Analyst Count
  • CPSS 0
  • CRDF 5
  • Target Price
  • CPSS N/A
  • CRDF $11.10
  • AVG Volume (30 Days)
  • CPSS 16.0K
  • CRDF 1.1M
  • Earning Date
  • CPSS 10-30-2025
  • CRDF 11-06-2025
  • Dividend Yield
  • CPSS N/A
  • CRDF N/A
  • EPS Growth
  • CPSS N/A
  • CRDF N/A
  • EPS
  • CPSS 0.80
  • CRDF N/A
  • Revenue
  • CPSS $192,257,000.00
  • CRDF $545,000.00
  • Revenue This Year
  • CPSS $143.76
  • CRDF N/A
  • Revenue Next Year
  • CPSS $14.32
  • CRDF N/A
  • P/E Ratio
  • CPSS $10.82
  • CRDF N/A
  • Revenue Growth
  • CPSS 2.04
  • CRDF N/A
  • 52 Week Low
  • CPSS $6.67
  • CRDF $1.90
  • 52 Week High
  • CPSS $12.73
  • CRDF $5.64
  • Technical
  • Relative Strength Index (RSI)
  • CPSS 54.68
  • CRDF 36.50
  • Support Level
  • CPSS $8.13
  • CRDF $2.03
  • Resistance Level
  • CPSS $8.61
  • CRDF $2.27
  • Average True Range (ATR)
  • CPSS 0.40
  • CRDF 0.12
  • MACD
  • CPSS 0.12
  • CRDF 0.04
  • Stochastic Oscillator
  • CPSS 86.11
  • CRDF 31.91

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Share on Social Networks: